P09.01 Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Aoki, T., Arakawa, Ueba, Oda, Nishida, Akiyama, Tsukahara, Iwasaki, Mikuni, Miyamoto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
POSTER PRESENTATIONS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464313/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.259
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia